Glucosamine and Joint Pain: The Evidence Has Changed

In the early 2000s, glucosamine and chondroitin looked like the answer to osteoarthritis. The GAIT trial, published in the New England Journal of Medicine in 2006, generated enormous excitement when it suggested the combination might benefit a subset of patients with moderate-to-severe knee pain. Nearly two decades of follow-up research has systematically dismantled that optimism.

What the GAIT Trial Actually Found

The GAIT trial (Clegg et al., NEJM, 2006) was an NIH-funded multicentre RCT of 1,583 patients with symptomatic knee osteoarthritis randomized to glucosamine 1500 mg/day, chondroitin 1200 mg/day, the combination, celecoxib 200 mg/day, or placebo for 24 weeks. The primary outcome — a 20% reduction in knee pain — was not significantly different for any supplement arm versus placebo (placebo response rate 60.1%). Celecoxib reached significance (10 percentage points above placebo). The widely circulated "moderate-to-severe pain subgroup" benefit was a stratified analysis (n=354) and is hypothesis-generating, not confirmatory.

The Subsequent Evidence

Multiple large independent trials since 2006 — including the LEGS study and the MOVES trial (Hochberg et al., Annals of the Rheumatic Diseases, 2015; n=606) — found glucosamine plus chondroitin produced pain reduction comparable to celecoxib but with a high placebo response and without consistent superiority over placebo when funded independently of manufacturers. The 2005 Cochrane review of 20 RCTs (Towheed et al.) found glucosamine sulfate from the Rotta preparation outperformed placebo on pain and function, but non-Rotta preparations did not. Gregori et al.'s 2018 network meta-analysis in JAMA covered 47 long-duration RCTs (≥12 months) involving 22,037 patients and found uncertainty in pain estimates for nearly every comparator vs placebo, with only glucosamine sulfate retaining a significant pain estimate after sensitivity analysis.

Current Clinical Guidelines

OARSI, the ACR, EULAR, and NICE all conditionally recommend against routine use of glucosamine and chondroitin for OA, citing insufficient evidence of benefit. Exercise, weight management, and physical therapy have substantially stronger evidence for symptom management in OA than any supplement.